Limited impact of short-term disruptions, growth momentum to continue in FY 23
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Company expects strong organic growth in sales, EBITDA in 2022
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
This has further strengthened its manufacturing presence in the United States of America
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Subscribe To Our Newsletter & Stay Updated